Quantcast
Last updated on April 19, 2014 at 7:10 EDT

Latest Astellas Pharma Inc. Stories

2012-10-22 07:29:08

NORTHBROOK, Ill., Oct. 22, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that MYRBETRIQ(TM) (mirabegron) extended-release tablets, indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency, is now available through U.S. pharmacies. "The availability of MYRBETRIQ marks an important milestone in our ongoing...

2012-10-01 14:21:20

HORSHAM, Pa., Oct. 1, 2012 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen") announced today that it has entered into a license agreement with Astellas Pharma Inc. ("Astellas") for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for moderate-to-severe rheumatoid arthritis (RA), following a successful Phase 2a study demonstrating its...

2012-09-24 06:26:59

NORTHBROOK, Ill., Sept. 24, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. Developed by Astellas, tacrolimus...

2012-09-14 06:26:24

NORTHBROOK, Ill., Sept. 14, 2012 /PRNewswire/ -- More than generosity of spirit drives employees at Astellas Pharma US, Inc. (Astellas Pharma US), a subsidiary of Tokyo-based Astellas Pharma Inc. (Astellas), to participate in the company's annual corporate social responsibility initiative, Changing Tomorrow Day, that wraps up today. A personal connection to the locations and a close tie to the company's mission of improving the lives of patients drive employees to volunteer. For...

2012-08-05 18:21:53

TOKYO, Aug. 6, 2012 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it decided to close Urogenix, Inc. ("Urogenix", Durham, NC, President: Shuuichi Tawara), an Astellas subsidiary, which is a research facility focusing on drug discovery in the field of urology. The closure will be completed by the end of December 2012. Urogenix currently employees thirteen scientists and staff. In March 2006, Astellas acquired this research...

2012-07-25 06:25:00

TOKYO, July 25, 2012 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and Fujita Health University (Aichi, President: Yoshikazu Kurosawa) announced that Astellas Research Institute of America LLC (ARIA), in collaboration with Dr. Tsuyoshi Miyakawa at Institute for Comprehensive Medical Science, Fujita Health University and Stanley Medical Research Institute (SMRI), has discovered deficits in maturation steps of neurogenesis within the...

2012-07-22 22:20:44

WAYNE, N.J., SOUTH SAN FRANCISCO, Calif. and TOKYO, July 23, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), and Astellas Pharma Inc. (TSE: 4503) today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva(®) (erlotinib) tablets to Nexavar(®) (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone. The SEARCH (Sorafenib...

2012-06-28 10:25:29

NORTHBROOK, Ill., June 28, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) has approved Myrbetriq(TM) (mirabegron) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. "Myrbetriq is the first oral OAB treatment with a distinct mechanism of action since the...

2012-06-13 10:24:14

KISSIMMEE, Fla., June 13, 2012 /PRNewswire/ -- Give Kids The World Village (GKTW) will host its largest single contingent of volunteers in its history on Wednesday, June 13, when more than 1,300 Astellas Pharma US, Inc. employees trade their iPhones and corporate focus for brushes, rakes and wrapping paper to help make dreams come true for children with life-threatening diseases. In town for the company's annual national sales meeting in Orlando, the Astellas volunteers...

2012-06-04 14:23:04

TOKYO and SAN DIEGO, June 4, 2012 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations. The trial will enroll approximately 64 adult patients (the estimated enroll of the protocol) in the United States and Europe to evaluate two oral doses of quizartinib in...